Targeting JNK3 for the treatment of neurodegenerative disorders

Drug Discovery Today

Volumn 9, Issue 21, 2004, Pages 932-939

  Resnick, Lynn ^a   Fennell, Myles ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Biochemistry; Drug Discovery; Neurobiology; Parkinson's disease; Peptide inhibitors; Pharmaceutical Science; Physiological regulators; Stroke

Indexed keywords

ACETONITRILE DERIVATIVE; AMINE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; KETONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIME DERIVATIVE; PHENYL GROUP; PYRIMIDINE DERIVATIVE; RECOMBINANT DNA; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING SITE; C JUN N TERMINAL KINASE 3 GENE; CORRELATION ANALYSIS; CROSS LINKING; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE TARGETING; HUMAN; HUMAN GENOME; IC 50; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; RECOMBINANT GENE; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL DETECTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STROKE; STRUCTURE ANALYSIS;

DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 10; NEURODEGENERATIVE DISEASES;

EID: 6344219718     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03251-9     Document Type: Review

References (78)

1. Linock J., et al. Activation of JNK3α1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3α1. Biochemistry. 39:2000;3141-3148
2. Ip Y.T., Davis R.J., et al. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol. 10:2003;205-219
3. Morrison D.K., Davis R.J., et al. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell Dev. Biol. 19:2003;91-118
4. Mohit A.A., et al. P493F12 Kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron. 14:1995;67-78
5. Dong C., et al. Defective T cell differentiation in the absence of JNK1. Science. 282:1998;2092-2095
6. + T cells to Th1 cells requires MAP kinase JNK2. Immunity. 9:1998;575-585
7. Kuan C.Y., et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 22:1999;667-676
8. Chang L., et al. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev. Cell. 4:2003;521-533
9. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766
10. Morishima Y., et al. β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21:2001;7551-7560
11. Zhu X., et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76:2001;435-441
12. Renolds C.H., et al. Stress activated protein kinase/c-Jun N-terminal kinase phosphorylates τ protein. J. Neurochem. 68:1997;1736-1744
13. Sato S., et al. Aberrant tau phosphorylation by glycogen synthase kinase-3β and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 277:2002;42060-42065
14. Cintron M., et al. β-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol. Sci. 25:2004;92-97
15. Savage M.J., et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 22:2002;3376-3385
16. Van Dam H., et al. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-Jun induction in response to genotoxic agents. EMBO J. 14:1995;1798-1811
17. Hunot S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101:2004;665-670
18. Wu D.C., et al. Activation of mitogen-activated protein kinases after permanent cerebral artery occlusion in mouse brain. J. Cereb. Blood Flow Metab. 20:2000;1320-1330
19. Yang D.D., et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 389:1997;865-870
20. Kuan C-Y., et al. A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:2003;15184-15189
21. Ho D.T., et al. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J. Biol. Chem. 278:2003;32662-32672
22. Dickens M., et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 277:2002;693-696
23. Whitmarsh A.J., et al. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science. 281:1998;1671-1674
24. Park H.S., et al. Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. EMBO J. 20:2002;446-456
25. McDonald P.H., et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 290:2000;1574-1577
26. Miller W.E., et al. Identification of a motif in the carboxyl terminus of beta-arrestin 2 responsible for activation of JNK3. J. Biol. Chem. 276:2001;27770-27777
27. Miller W.E, Lefkowitz R.J., et al. Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. Curr. Opin. Cell Biol. 13:2001;139-145
28. Gupta S., et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2002;2760-2770
29. Barr R.K., et al. Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277:2002;10987-10997
30. Borsello T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9:2002;1180-1186
31. Heo Y.S., et al. Structural basis for the selective inhibition of JNK1 by scaffolding protein JIP1 and SP600125. EMBO J. 23:2004;2185-2195
32. Scapin G., et al. Structural biology in drug design: selective protein kinase inhibitors. Drug Discov. Today. 7:2002;601-611
33. Scapin G., et al. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 10:2003;705-712
34. Xie X., et al. Vertex Pharmaceuticals. Crystallizable JNK complexes. 1999;2996-3007. WO 9957253 A2
35. Kallunki T., et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8:1994;2996-3007
36. Lograsso P., et al. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors. 2001;. WO 2001091749 A1
37. Carboni S., et al. A JNK inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther. 310:2004;25-32. AS601245:
38. Halazy S., et al. Applied Research Systems. Benzazole derivatives and their use as JNK modulators. 2001;. EP 1110957 A1
39. Gaillard P., et al. Applied Research Systems. Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders. 2003;. WO 03091249 A1
40. Gaillard P., et al. Applied Research Systems. Azole methylidene cyanide derivatives and their use as protein kinase modulators. 2003;. WO 2003106455
41. Cao J., et al. Vertex Pharmaceuticals. Preparation of thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases. 2002;. WO 2002083667
42. Ledeboer M., et al. Vertex Pharmaceuticals. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases. 2002;. WO 0246184 A1
43. Harrington E., et al. Vertex Pharmaceuticals. Preparation of isoxazole derivatives as inhibitors of Src and other protein kinases. 2002;. US 2003207873 A1
44. Moon Y-C., et al. Vertex Pharmaceuticals. Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors of Src and other protein kinases. 2002;. WO 2002092573 A2
45. Harrington E., et al. Vertex Pharmaceuticals. Preparation of isoxazole derivatives as inhibitors of Src and other protein kinases. 2002;. WO 2002083668
46. Ledeboer M., et al. Vertex Pharmaceuticals. Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities. 2004;. WO 2004005283 A1
47. Green J., et al. Vertex Pharmaceuticals. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases. 2002;. WO 0112621 A1
48. Bethiel R., et al. Vertex Pharmaceuticals. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases. 2002;. WO 2002079197 A1
49. Graczyk P., et al. Eisai. Jun kinase inhibitors. 2002;. WO 2002081475 A1
50. Alberti M., et al. Glaxo Group. Preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases. 2002;. WO 2002016359 A1
51. Ohkawa S., et al. Takeda Chemical Industries. Preparation of azoles as JNK inhibitors. 2002;. WO 2002062792 A1
52. Kois A., et al. Signal Pharmaceuticals. Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto. 2002;. WO 0246170 A2
53. Bennett B.L., et al. Signal Pharmaceuticals. Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto. 2001;. WO 0112609 A1
54. Sakata S.T., et al. Signal Pharmaceuticals. Anthrone derivatives and their use as JNK inhibitors. 2002;. WO 2002066450 A2
55. Bennett B., et al. SP600125, an anthrapyrazole inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13681-13686
56. Bain J., et al. The specificities of protein kinase inhibitors: an update. Biochem. J. 371:2003;199-204
57. Wang W., et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in th eMPTP model of Parkison's diesease. Neurosci. Res. 48:2002;195-202
58. Arkinstall S., et al. Applied Research Systems. Pharmaceutically active sulfonamide derivatives. 2001;. EP 1088821 A1
59. Halazy S., et al. Applied Research Systems. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Jun kinases. 2002;. EP 1193268 A1
60. Halazy S., et al. Applied Research Systems. Pharmaceutically active sulfonamide derivatives as inhibitors of protein Jun kinases. 2002;. EP 1193267 A1
61. Arkinstall S., et al. Applied Research Systems. Pharmaceutically active sulfonyl hydrazide derivatives. 2001;. WO 0123382 A1
62. Halazy S., et al. Applied Research Systems. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins. 2002;. EP 1193256 A1
63. Rueckle T., et al. Applied Research Systems. Arylsulfonamide derivatives as c-Jun N-terminal kinases (JNK's) inhibitors. 2002;. WO 2003010164
64. Arkinstall S., et al. Applied Research Systems. Pharmaceutically active sulfonyl amino acid derivatives. 2001;. EP 1088815 A1
65. Arkinstall S., et al. Applied Research Systems. Pharmaceutically active sulfonyl hydrazide derivatives. 2001;. EP 1088822 A1
66. Grazyk P., et al. Eisai. Preparation of 7-azaindoles as inhibitors of c-Jun N-terminal kinases. 2003;. WO 2003082869 A1
67. Graczyk P., et al. Eisai. Preparation of 7-azaindoles as inhibitors of c-Jun N-terminal kinases for treatment of neurodegenerative disorders. 2003;. WO 2003082868 A1
68. Ohi N., et al. Eisai. Pyrazole compound and medicinal composition containing the same. 2003;. WO 2003101968
69. Oinuma H., et al. Eisai. Novel 1H-indazole compond. 2002;. WO 20022083648
70. Malmstroem J., Swahn B-M., et al. AstraZeneca AB. Preparation of indazoles as inhibitors of Jun N-terminal kinases (JNK), in particular JNK3. 2003;. WO 2003068754 A1
71. Bhagwat S.S., et al. Signal Pharmaceuticals. Indazole derivatives as JNK inhibitors and compositions and methods related thereto. 2002;. WO 0210137 A2
72. Ohi N., et al. Eisai. Preparation of Novel fused ring indazole derivatives as JNK inhibitors. 2003;. WO 2004050088 A1
73. Kanai F., et al. Kyowa Hakko Kogto. JNK Inhibitor. 2004;25-32. WO 2004050088 A1
74. Bhagwat S.S., et al. Signal Pharmaceuticals. Methods for treating an inflammatory condition or inhibiting JNK. 2004;. US 20040127536 A1
75. Corbett W., et al. Hoffmann-La Roche AG. 4-Aryloxindoles as inhibitors of JNK protein kinases. 2000;. WO 0035909 A1
76. Luk K-C., et al. Hoffmann-La Roche AG. 4- and 5-Alkynyloxindoles and 4- and 5-alkenyloxindoles. 2000;. WO 0035906 A2
77. Luk K-C., et al. Hoffmann-La Roche AG. 4- and 5-Alkynyloxindoles and 4- and 5-alkenyloxindoles. 2000;. WO 0035921
78. Salituro F., et al. Vertex Pharmaceuticals. Inhibitors of c-Jun N-terminal kinases (JNK). 2000;. WO 0064872 A1